KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

Sandra Misale; Jackson P. Fatherree; Eliane Cortez; Chendi Li; Samantha Bilton; Daria Timonina; David T. Myers; Dana Lee; María Gomez‐Caraballo; Max Greenberg; Varuna Nangia; Patricia Greninger; Regina K. Egan; Joseph McClanaghan; Giovanna T. Stein; Ellen Murchie; Patrick P. Zarrinkar; Matthew R. Janes; Lian‐Sheng Li; Yi Liu; Aaron N. Hata; Cyril H. Benes

doi:10.1158/1078-0432.ccr-18-0368

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Our findings suggest that signaling adaptation can in some instances limit the efficacy of ARS1620 but combination with PI3K inhibitors can overcome this resistance.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Misale et al. (2018) studied this question.

synapsesocial.com/papers/69e783f1b1f585b14520bf4b https://doi.org/10.1158/1078-0432.ccr-18-0368

View at Publisher

Ask AI

Bookmark

Share

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

Ask about this paper

Abstract

Discussion

Cite This Study

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading